Welcome to AiCuris: The Powerhouse for Anti-infectives
“Committed to making the difference”
AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).
Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.
AiCuris launches “PREP"
|
| AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference |
- PREP is a comprephensive four-pillar program to help prevent future pandemics and combat antimicrobial resistance (AMR)
- Exploring opportunities of AiCuris pipeline products to treat Corona; clinical trial with first drug candidate AIC649 with the potential to become a first-line pandemic therapy under preparation
- Company commits to driving drug development in resistance breaking antibiotics based on novel scientific approaches
- AiCuris initiates “AiCubator”, providing long-term support for early but promising research projects in the field of anti-infectives
- Pursuit of an active licensing strategy for pre-clinical and early clinical projects in the anti-infective space to expand the Company’s portfolio
- AiCuris to participate in several AMR panels and to discuss partnering opportunities at upcoming virtual 4th AMR Conference
AiCuris joins IMI Consortium against Corona
|
| AiCuris is partner in Europe’s largest initiative to accelerate therapy development for COVID-19 and future Coronavirus threats (CARE) |
- CARE (Corona Accelerated R&D in Europe), supported by Europe’s Innovative Medicines Initiative (IMI), is the largest undertaking of its kind dedicated to discovering and developing urgently needed treatment options for COVID-19.
- The initiative is committed to a long-term understanding of the disease and development of therapies for COVID-19 and future coronavirus threats in addition to urgent efforts to repurpose existing therapies as potential immediate response.
- The CARE consortium will accelerate COVID-19 R&D by bringing together the leading expertise and projects of 37 teams from academic and non-profit research institutions and pharmaceutical companies into a comprehensive drug discovery engine.
Breakthrough Therapy Designation
|
| AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients |
- Receiving Breakthrough Therapy Designation will facilitate AiCuris goal of bringing pritelivir to patients as quickly as possible
- AiCuris is currently preparing to add a pivotal Phase 3 trial part to the ongoing Phase 2 study in immunocompromised patients whose HSV infections have become resistant to acyclovir as a basis for NDA submission
- The company to discuss partnering opportunities at upcoming BIO Digital